Cancer Therapeutics Program

摘要：癌症治疗学(CT) 癌症治疗(CT)计划的首要目标是开发创新的方法来 发现、设计、开发和验证治疗肺癌的新型抗癌药物和联合方案 人类癌症。为了实现这一使命，该方案侧重于三个主要主题：(1)发现和发展 在临床前环境中，新的靶点和分析方法来补充药物发现的创新方法， 新药物和联合方案；(2)研究新药物和现有药物的作用机制 抗癌药物；以及(3)进行早期(I/II)临床试验，重点是UPMC Hillman的翻译 癌症中心(HCC)科学和新制剂的发现，以及与国家癌症研究所的合作 癌症研究所(NCI)、NCI癌症中心、其他学术中心、合作团体和行业。这个 成功执行这一任务的战略需要整个基础、 临床前和临床/转化性研究。在亚当·布鲁夫斯基、医学博士、爱德华博士的领导下 朱，医学博士和Peter Wipf，博士，CT有58名成员，代表16个学院和5个学院 在匹兹堡大学。CT成员开展以癌症为重点的研究，共资助1490万美元 年度直接成本资金，其中280万美元是NCI资金，200万美元是其他同行审查，1010万美元是非 同行评议。从2015年到2019年8月，CT成员出版了1116份与癌症相关的出版物 占计划内协作的26%，计划间协作的41%，机构间协作的%。肝细胞癌 支持，包括临床方案和数据管理以及所有共享资源，极大地促进和 加强CTP研究。

Abstract: Cancer Therapeutics (CT) The overarching goal of the Cancer Therapeutics (CT) Program is to develop innovative approaches to discover, design, develop, and validate novel anticancer agents and combination regimens for the treatment of human cancers. To achieve this mission, the Program focuses on three main themes: (1) discover and develop in a pre-clinical setting, novel targets and assays to complement the innovative approaches to drug discovery, novel agents, and combination regimens; (2) investigate the mechanisms of action of new and existing anticancer agents; and (3) conduct early-phase (I/II) clinical trials with a focus on translation of UPMC Hillman Cancer Center (HCC) science and discoveries of novel agents, as well as in partnership with the National Cancer Institute (NCI), NCI cancer centers, other academic centers, cooperative groups, and industry. The strategy for successfully carrying out this mission requires the involvement of the entire continuum of basic, preclinical, and clinical/translational research. Under the leadership of Adam Brufsky, MD, PhD, Edward Chu, MD and Peter Wipf, PhD, CT has 58 members representing 16 academic departments and 5 schools within the University of Pittsburgh. CT members conduct cancer-focused research supported by $14.9M in total annual direct costs funding, of which $2.8M is NCI funding, $2.0M is other peer-reviewed, and $10.1M is non- peer reviewed. From 2015-August 2019, CT members published 1,116 cancer-related publications representing 26% intra-programmatic, 41% inter-programmatic and 64% inter-institutional collaborations. HCC support, including Clinical Protocol and Data Management and all Shared Resources, greatly facilitate and enhance CTP research.